Core Viewpoint - A class action has been filed against POMDoctor Ltd. for allegedly engaging in a "pump-and-dump" scheme that misled investors prior to its IPO, resulting in significant financial losses for shareholders [1]. Allegations - POMDoctor's share price increased from the IPO price of $4.00 to a peak of $6.09 before crashing approximately 91% to $0.50 on December 10, 2025, with the current price around $0.40 [1]. - The company is accused of using social media to promote false information and impersonating financial advisors to create a buying frenzy among retail investors [1]. - The complaint alleges that POMDoctor failed to disclose critical information regarding the stock promotion scheme and the involvement of insiders in the coordinated selling of shares [1]. Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 7, 2026, and participation in the case is not required to be eligible for recovery [1]. - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees unless they recover losses [1].
POM Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against POMDoctor Ltd.